U.S., April 10 -- ClinicalTrials.gov registry received information related to the study (NCT07520006) titled 'Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies' on April 02.
Brief Summary: The study will evaluate NX-5948 (bexobrutideg) in combination with venetoclax with or without an anti-CD20 antibody (rituximab or obinutuzumab) in second-line or higher (2L+) relapsed/refractory (R/R) or first-line (1L) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Study Start Date: May, 2026
Study Type: INTERVENTIONAL
Condition:
B-cell Lymphoma
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Intervention:
DRUG: NX-5948
Administered orally once daily as a capsule
DRUG: venetoclax
...